Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial

Sandborn, William J.; Panés, Julián; Zhang, Haiying; Yu, Dahong; Niezychowski, Wojciech; Su, Chinyu

doi:10.1053/j.gastro.2015.09.001

Cited by 88 publications

(58 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The benefit/risk imbalance and cost/efficacy ratio have been considered: the test is already refunded in some European countries. Therefore, fecal calprotectin is a non-invasive marker that can objectively assess mucosal healing, and its use is now systematically recommended not only for IBD diagnosis [72] but also in protocols evaluating new treatments [31,73].…”

Section: Medico-economic Aspectsmentioning

confidence: 99%

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Manceau

Chicha-Cattoir²,

Puy

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBDs) are chronic diseases that result from the inflammation of the intestinal wall, suspected in any patient presenting with intestinal symptoms. Until recently, the diagnosis was mainly based on both clinical and endoscopic arguments. The use of an easy, fast, reliable, non-invasive, and inexpensive biological assay is mandatory not only in diagnosis but also in evolutionary and therapeutic monitoring. To date, the fecal calprotectin is the most documented in this perspective. This marker allows the discrimination between functional and organic bowel processes with good performance. The determination of the fecal calprotectin level contributes to the evaluation of the degree of disease activity and to monitoring of therapeutic response.

show abstract

Section: Medico-economic Aspectsmentioning

confidence: 99%

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Manceau

Chicha-Cattoir²,

Puy

et al. 2017

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…133,134 Lower FC levels have been associated with response to biologic therapy and clinical outcomes including clinical remission and mucosal healing. 135,136 Perhaps most useful, among patients in remission, FC has been reported to increase earlier and remain elevated prior to clinical or endoscopic relapse of disease, 137 which may indicate a role for prospective or routine monitoring with FC to identify those patients at greatest risk of relapse.…”

Section: Future Directions For Biomarkersmentioning

confidence: 99%

New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

Barnes

Burakoff²

2016

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Despite advances in our understanding of the pathophysiology underlying Inflammatory Bowel Disease (IBD), there remains a significant need for biomarkers that can differentiate between Crohn's Disease (CD) and Ulcerative Colitis (UC) with high sensitivity and specificity, in a cost-efficient manner. As the focus on personalized approaches to the delivery of medical treatment increases, new biomarkers are being developed to predict an individual's response to therapy as well as their overall disease course. In this review, we will outline many of the existing and recently developed biomarkers, detailing their role in the assessment of patients with IBD. We will identify opportunities for improvement in our biomarkers, including better differentiation between the subtypes of IBD. We will also discuss new targets and strategies in biomarker development, including combining modalities to create biomarker signatures to improve the ability to predict disease courses and response to therapy among individual patients.

show abstract

“…In fact, a significant difference could be observed in other biomarkers (13). Sanborn WJ and colleagues conducted a study on 194 patients with ulcerative colitis and showed that setting "150" as a cut off for calprotectin does not have a proper accuracy for categorizing patients from the clinical severity and endoscopic point of view (14).…”

Section: Discussionmentioning

confidence: 99%

The Relation Between Fecal Calprotectin and the Rate of Clinical Activity of Ulcerative Colitis

et al. 2018

View full text Add to dashboard Cite

Background: Inflammatory bowel disease is a disorder with unknown origin in which environment, genetics, and immunity play a part. Although colonoscopy and biopsy are expensive and invasive, are used to monitoring the mucosal inflammation. Fecal calprotectin is a non-invasive test which has attracted a lot of attention. We aimed to determine the relation of fecal calprotectin and clinical activity of ulcerative colitis. Methods: This cross-sectional study took place with the confirmation of ethics committee of Mashhad University of Medical Sciences in 2014 -2015. Patients with diagnosis of ulcerative colitis were included; demographic information was recorded and clinical activity of disease was evaluated. Fecal calprotectin was measured by the quantitative ELISA method and results of laboratory studies and clinical examinations were analyzed by SPSS software version 16. Level of significance was considered less than 0.05.

show abstract

Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial

Cited by 88 publications

References 36 publications

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

Fecal calprotectin in inflammatory bowel diseases: update and perspectives

New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes

The Relation Between Fecal Calprotectin and the Rate of Clinical Activity of Ulcerative Colitis

Contact Info

Product

Resources

About